The Burrill Report


The Burrill Report (February 24, 2014): The Case for Megamergers (.MP3,11.07 Mb)

Megamergers, according to conventional wisdom, are more likely to destroy rather than create value. But a new study from McKinsey & Company finds in the pharmaceutical industry, the numbers suggest otherwise. The analysis argues that these deals have been critical for the longer-term sustainability of acquirers. We spoke to Myoung Cha, principal in the Silicon Valley of McKinsey and co-author of the report, about the study, how deals aimed at consolidation fared relative to deals focused on driving growth, and why the benefits often justify the disruption these deals create.

You can read the McKinsey analysis here. 


February 21, 2014
http://www.burrillreport.com/article-the_case_for_megamergers.html